Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Lymphocytes may hinder hair stem cells, causing hair loss without scarring.

Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.

Certain HLA class II alleles increase or decrease the risk of alopecia areata.

Anti-TNF-α therapy may increase the risk of developing alopecia areata, especially in those with a history of autoimmune disease.

New techniques have enhanced our understanding of how stem cells function and the role of mutations in aging tissues, which may influence future cancer therapies.

Mesenchymal stem cells from laser-assisted liposuction are as effective and safe as those from conventional methods for cell therapy.

Tofacitinib is an effective and safe treatment for alopecia areata.

Targeting SIRT1 with antisense oligonucleotides could be a promising treatment for hair loss.

Trichohyalin may trigger the immune response causing alopecia areata.

Statins may help treat alopecia areata by reducing harmful immune interactions.

Arg1+ macrophages may play a role in causing alopecia areata.

Plasmacytoid dendritic cells are a key factor in causing hair loss in alopecia areata and could help differentiate it from other hair loss conditions.

Prostanoids help regulate immune cells, affecting inflammation and cancer.

Lysophosphatidic acid boosts stem cell growth and movement by creating reactive oxygen species.

Atoh1 expression can create new Merkel cells in the skin.

Skin cells and immune cells change in a skin condition called hidradenitis suppurativa, and a certain treatment can improve these changes.

New treatments for alopecia areata, like JAK inhibitors and immunomodulators, are promising.

Skin tumor cells in patients with tuberous sclerosis have higher levels of a protein called cathepsin B.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

New treatments for alopecia areata focus on targeting immune responses for better results.

Injecting recipient splenocytes into donors' thymus can prevent graft-versus-host disease.

Stem cells are in deep skin layers, while differentiating cells are in shallow layers.

Squaric acid dibutylester promotes hair growth by activating immune cells, especially macrophages.

Lower TGFß1 levels help stem cells become beige fat cells.

Type 2 cytokines IL-4 and IL-13 increase skin's vulnerability to Staphylococcus aureus, which could be important for treating atopic dermatitis.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Unconventional lymphocytes are important for quick immune responses and healing of skin and mucosal barriers.